Oppenheimer analyst Jeff Jones lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $52.00 (from $54.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE